Search
Menu
Home
HTB
2022
February
HTB
February 2022
Contents
Editorial
HTB: no. 1/2 (January/February 2022)
i-Base appeal: please support i-Base with £5 or £10 a month
Conference reports
CROI 2022 to only be virtual: programme online
Antiretrovirals
US FDA approves 2-monthly dosing option for long-acting injectable cabotegravir/rilpivirine
Gilead to pay $1.25 billion plus royalties to ViiV Healthcare for bictegravir infringing on dolutegravir patent
Guidelines
BHIVA interim guidance on long-acting cabotegravir and rilpivirine injections
Coinfections and complications
HIV-associated reductions in telomere length are stopped by effective ART
Resistance
Drug resistance profile of integrase inhibitors when treating HIV-2
Other news
EACS HIV Summer School 2022: Applications are open
COVID-19: investigational drugs
UK RECOVERY study shows no benefit from aspirin in people hospitalised with COVID-19
COVID-19: guidelines
IDSA update COVID-19 guidelines (January 2022)
Job vacancies
i-Base vacancy: HIV treatment advocate and information officer
PDFs
HTB: no. 1/2 – plus HIV and COVID-19 (7 February 2022)
HTB RSS
Early access
Doravirine studies at Glasgow 2022
6 February 2023
Pipeline studies at Glasgow 2022
6 February 2023
Long-acting cabotegravir/rilpivirine: Adverse events, implementation and PROMs
6 February 2023
Lenacapavir approved in the US for multidrug resistant HIV
6 February 2023
All early access reports
Current issues
February 2023
January 2023
December 2022
Back issues
Special report
Latest statistics on HIV in the UK: data for 2021
1 December 2022
More from HTB
Conference reports
Conference shortcuts
Articles by subject
PDFs
Subscribe
HTB homepage
Home
i-Base homepage